Olanzapine augmentation in treatment-resistant panic disorder: A 12-week, fixed-dose, open-label trial

Journal of Clinical Psychopharmacology

Volumn 26, Issue 1, 2006, Pages 45-49

  Sepede, Gianna ^a   De Berardis, Domenico ^a   Gambi, Francesco ^a   Campanella, Daniela ^a   La Rovere, Raffaella ^a   D'Amico, Michele ^a   Cicconetti, Alessandra ^a   Penna, Laura ^a   Peca, Silvana ^a   Carano, Alessandro ^a   Mancini, Enrico ^a,b   Salerno, Rosa Maria ^a   Ferro, Filippo Maria ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF URBINO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; CITALOPRAM; FLUOXETINE; IMIPRAMINE; LORAZEPAM; OLANZAPINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; AGORAPHOBIA; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DROWSINESS; FEMALE; HAMILTON ANXIETY SCALE; HUMAN; INCREASED APPETITE; MALE; MEDICAL ASSESSMENT; PANIC; PRIORITY JOURNAL; QUESTIONNAIRE; RATING SCALE; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; XEROSTOMIA;

ADULT; AGORAPHOBIA; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; PANIC DISORDER; PAROXETINE; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; TREATMENT FAILURE;

EID: 31544451260     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000195108.01898.17     Document Type: Article

References (23)

1. Weissman MM, Bland RC, Canino GJ, et al. The cross national epidemiology of panic disorder. Arch Gen Psychiatry. 1997;54:305-309.
2. Sheehan DV. The management of panic disorder. J Clin Psychiatry. 2002;63:17-21.
3. Liebowitz MR. Panic disorder as a chronic illness. J Clin Psychiatry. 1997;58:5-8.
4. Zamorski MA, Albucher RC. What to do when SSRIs fail: eight strategies for optimizing treatment of panic disorder. Am Fam Phys. 2002;66:1477-1484.
5. Etxebeste M, Aragues E, Malo P, et al. Olanzapine and panic attacks. Am J Psychiatry. 2000;157:659-660.
6. Khaldi S, Kornreich C, Dan B, et al. Usefulness of olanzapine in refractory panic attacks. J Clin Psychopharmacol. 2003;23:100-101.
7. Chao IL. Olanzapine augmentation in panic disorder: a case report. Pharmacopsychiatry. 2004;37:239-240.
8. Hollifield M, Thompson PM, Ruiz JE, et al. Potential effectiveness and safety of olanzapine in refractory panic disorder. Depress Anxiety. 2005;21:33-40.
9. Dannon PN, Iancu I, Grunhaus L. The efficacy of reboxetine in the treatment-refractory patients with panic disorder: an open label study. Hum Psychopharmacol. 2002;17:329-333.
10. Sheehan DV. Sheehan Anxiety and Panic Attack Scales. Kalamazoo, Mich: Upjohn; 1983.
11. Doyle AC, Pollack MH. Establishment of remission criteria for anxiety disorders. J Clin Psychiatry. 2003;64:40-45.
12. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. New Jersey: Lawrence Erlbaum; 1988.
13. Koran LM, Ringold AL, Elliott MA. Olanzapine augmentation in treatment-refractory obsessive-compulsive disorder. J Clin Psychiatry. 2000;61:514-517.
14. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating refractory major depression. Am J Psychiatry. 2001;158:131-134.
15. D'Amico G, Cedro C, Muscatello MR, et al. Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder. Prog Neuro-Psychopharmacol Biol Psychiatry. 2003;27:619-623.
16. Weimer E, Braus DF, Cavus I, et al. Augmentation of selective serotonin reuptake inhibitors (SSRI) with atypical antipsychotics in the treatment of depression. Fortschr Neurol Psychiatr. 2002;70:210-217.
17. Gorman JM, Kent JM, Sullivan GM, et al. Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry. 2000;157:493-505.
18. Spina E, Scordo MG. Newer antipsychotics: comparative review of drug interactions. Exp Rev Neurother. 2001;1:171-182.
19. Prior TI, Baker GB. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci. 2003;28:99-112.
20. Weigmann H, Gerek S, Zeisig A, et al. Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit. 2001;23:410-413.
21. Mathew SJ, Coplan JD, Gorman JM. Management of treatment-refractory panic disorder. Psychopharmacol Bull. 2001;35:97-110.
22. Birmaher B, Kennah H, Brent D, et al. Is bipolar disorder specifically associated with panic disorder in youths? J Clin Psychiatry. 2002;63:414-419.
23. Soutullo CA, Sorter MT, Foster KD, et al. Olanzapine in the treatment of adolescent acute mania: a report of seven cases. J Affect Disord. 1999;53:279-283.